



<b>Combined Form PTO/SB/08A&amp;B</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<i>Complete if Known</i>	
		Application Number	10/673,380
		Confirmation Number	4353
		Filing Date	September 30, 2003
		First Named Inventor	Takashi NAKAGAWA et al.
		Art Unit	1647
		Examiner Name	Sandra L. Wegert
Sheet		of	Attorney Docket Number 031729

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		
		US			
		US			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
		European Search Report dated July 7, 2007 in PCT/JP0312472	
	1	SEBEKOVA ET AL.: "Systemic treatment with proteolytic enzymes in rat models of nonimmune mediated renal diseases" INTERNATIONAL JOURNAL OF IMMUNOTHERAPY, BIOSCIENCE EDIPRINT INC., vol. 13, no. ¾, 1997, pages 79-83.	
	2	EMANCIPATOR ET AL.: "Oral enzymes in different animal models of glomerulonephritis", INTERNATIONAL JOURNAL OF IMMUNOTHERAPY, BIOSCIENCE EDIPRINT INC., vol. 13, no. ¾, 1997, pages 97-103.	
	3	DAMIOAN BRUCE P ET AL.: "Cardiovascular responses mediated by protease-activated receptor-2 (PAR-2) and thrombin receptor (PAR-1) are distinguished in mice deficient in PAR-2 or PAR-1", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 288, no. 2, February 1999, pages 671-678.	
	4	CICALA CARLA ET AL.: "Protease-activated receptor-2 involvement in hypotension in normal and endotoxemic rats in vivo" CIRCULATION, vol. 99, no. 19, May 18, 1999, pages 2590-2597.	
	5	COCKS T M ET AL.: "A protective role for protease-activated receptors in the airways", NATURE, NATURE PUBLISHING GROUP, London, GB, vol. 398, March 11, 1999, pages 156-160.	
	6	SOBEY CHRISTOPHER G ET AL.: "Activation of 1-5 protease-activated receptor-2 (PAR-2) elicits nitric oxide-dependent dilatation of the basilar artery in vivo", STROKE, vol. 29, no. 7, July 1998, pages 1439-1444.	
	7	KAWABATA ATSUFUMI ET AL.: "The protease-activated reception-2 agonist induces gastric mucus secretion and mucosal cytoprotection", JOURNAL OF CLINICAL INVESTIGATION, vol. 107, no. 11, June 2001, pages 1443-1450.	
	8	IMANISHI M ET AL.: "Glomerular hypertension as one cause of albuminuria in Type II diabetic patients", DIABETOLOGIA, BERLIN, DE, vol. 42, no. 8, August 1999, pages 999-1005.	
Examiner Signature		Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or in the comment box of this document. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.